1. Dahan, R., B. C. Barnhart, F. Li, A. P. Yamniuk, A. Korman, J.V. Ravetch. .Therapeutic activity of agonistic, human anti-CD40 monoclonal Abs requires ive FcγR-engagement. .Cancer Cell ,2016,29(6):820-831. 2. Georgoudaki, A.M., K. Prokopec, E. Hellqvist, V. Boura, J. ?stling, S. Sohn, R.A. Harris, M. Rantalainen, D. Klevebring, M. Sund, J. Fuxe, C. Rolny, F. Li, J.V. Ravetch, M.C.I. Karlsson. .Reprogramming tumor associated macrophages by antibody targeting inhibits cancer progression and metastasis. .Cell Reports ,2016,15(9):2000-11. 3. Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, Shi H, Liu M, Du M, Taylor PR, Zhu HH, Chen J, Meng G, Li F, Chen C, Zhang Y, Jia XM, Lin X, Zhang X, Pearlman E, Li X, Feng GS, Xiao H. .Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses..Nature Immunology,2015,16:642-52. 4. Li, F#., P. Smith, and J. V. Ravetch#. .Inhibitory Fcgamma Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms. .Journal of immunology ,2014,192:3021-8 . 5. Simpson, T. R., F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. .Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.The Journal of experimental medicine,2013,210: 1695-1710. 6. Li, F#., and J. V. Ravetch#. .Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. .Proceedings of the National Academy of Sciences of the United States of America,2013,110: 19501-19506. 7. Smith, P., D.J. Dilillo, S. Bournazos, F. Li, and J.V. Ravetch.Mouse model recapitulating human Fcgamma receptor structural and functional diversity. .Proceedings of the National Academy of Sciences of the United States of America ,2012,109:6181-6186. 8. Li, F., and J. V. Ravetch.Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement..Proceedings of the National Academy of Sciences of the United States of America ,2012,109: 10966-10971. 9. Li, F., and J. V. Ravetch.A general requirement for FcgammaRIIB co-engagement of agonistic anti-TNFR antibodies..Cell cycle ,2012,11: 3343-3344. 10. Li, F., and J.V. Ravetch.Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. .Science ,2011,333:1030-1034. 11. Li, F., Y. Yan, J. Pieretti, D.A. Feldman, and L.A. Eckhardt. .Comparison of identical and functional Igh alleles reveals a nonessential role for Emu in somatic hypermutation and class-switch recombination. .Journal of immunology ,2010,185:6049-6057. 12. Li, F., and L.A. Eckhardt.A role for the IgH intronic enhancer E mu in enforcing allelic exclusion.The Journal of experimental medicine ,2009,206:153-167. 13. Zhang, B., A. Alaie-Petrillo, M. Kon, F. Li, and L.A. Eckhardt.Tranion of a productively rearranged Ig VDJC alpha does not require the presence of HS4 in the IgH 3 regulatory region. .Journal of immunology ,2007,178:6297-6306. 14. Romov, P.A., F. Li, P.N. Lipke, S.L. Epstein, and W.G. Qiu..Comparative genomics reveals long, evolutionarily conserved, low-complexity islands in yeast proteins. .Journal of molecular evolution,2006,63:415-425. 15. Garrett, F.E., A.V. Emelyanov, M.A. Sepulveda, P. Flanagan, S. Volpi, F. Li, D. Loukinov, L.A. Eckhardt, V.V. Lobanenkov, and B.K. Birshtein.Chromatin architecture near a potential 3 end of the igh locus involves modular regulation of histone modifications during B-Cell development and in vivo occupancy at CTCF sites.Molecular and cellular biology,2005,25:1511-1525. --> |
